Systemic Anti-Cancer Therapy Regimen Library
LUNG NSCLC Locally advanced/Metastatic - amivantamab
Treatment Overview
Recommended starting dose of amivantamab is dependent on the patient's weight at the initiation of therapy:
- For body-weight less than 80 kg the recommended starting dose is 1050 mg;
- For body-weight 80 kg or greater the recommended starting dose is 1400 mg.
Use the regimen below specific for the patient's weight.
Recommended starting dose for body-weight less than 80 kg.
Recommended starting dose for body-weight 80 kg or greater.
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Low |
| Hypersensitivity / Infusion related reaction risk: | High - routine premedication recommended |
References
Matthew Krebs et al., Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.. JCO 40, 9008-9008(2022). DOI:10.1200/JCO.2022.40.16_suppl.9008
Janssen-Cilag (New Zealand) Limited. Rybrevant New Zealand Datasheet 19 February 2024. https://www.medsafe.govt.nz/profs/datasheet/r/rybrevantinf.pdf (Accessed 06 August 2024).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.